| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $2,177,094 ) |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $255,758 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA260449 | Exploiting gold nanoparticle as a probe to identify therapeutic targets | 000 | 5 | NIH | 12/4/2025 | $319,463 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31AI189149 | Human gut Bacteroidales defense mechanisms against emerging antibacterial toxins | 000 | 2 | NIH | 12/29/2025 | $46,966 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 000 | 1 | NIH | 12/19/2025 | $41,422 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA298165 | A Randomized Factorial Trial of Varenicline with Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation | 000 | 2 | NIH | 12/17/2025 | $546,679 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $11,973 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $857,988 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $49,281 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | H7600185 | Ryan White Part C Outpatient EIS Program | 00 | 30 | HRSA | 12/29/2025 | $293,192 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG3CA290310 | Discovery and Development of Natural Products for Interception of CRC | 000 | 2 | NIH | 11/26/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R34DA060534 | Developing an Empowerment Theory-Based Smoking Cessation Intervention for People with High Levels of Social Stress | 000 | 2 | NIH | 12/5/2025 | -$222,227 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21EY035725 | Targeting Innate Inflammation Pathways to Treat Ocular Infections | 000 | 2 | NIH | 11/11/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK129656 | Understanding the metabolic pathology of pediatric obesity and NAFLD | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA253391 | Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | 000 | 5 | NIH | 11/13/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA255840 | Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence | 000 | 5 | NIH | 12/8/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K23DA062104 | A translational evaluation of depressive symptomology and smoking cessation treatment mechanisms for just-in-time-adaptive-interventions | 000 | 1 | NIH | 12/4/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K01MD015295 | HealthyCells: A Culturally-Tailored Smoking Cessation Smartphone Intervention for African Americans with Adjunctive Treatment for Sedentary Behavior | 000 | 5 | NIH | 11/12/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31AI179208 | Toxin B receptor mediated events in Clostridioides difficile disease | 000 | 2 | NIH | 12/4/2025 | -$23,401 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U1Q53063 | Geriatrics Workforce Enhancement Program | 02 | 2 | HRSA | 12/10/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 02 | 2 | HRSA | 11/19/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $82,940,078 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG072295 | Cerebromicrovascular rejuvenation by heterochronic blood exchange | 001 | 3 | NIH | 6/26/2025 | $433,349 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK139443 | Evaluating PQQ for preventing maternal obesity-induced fetal programming of juvenile NAFLD in Papio anubis | 000 | 2 | NIH | 3/5/2025 | $559,845 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK139443 | Evaluating PQQ for preventing maternal obesity-induced fetal programming of juvenile NAFLD in Papio anubis | 001 | 2 | NIH | 8/4/2025 | $62,204 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F30AG087705 | Regulation of Microglial Function by Major Histocompatibility Complex I in Aging and Alzheimer's Disease | 000 | 2 | NIH | 9/16/2025 | $44,477 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P20GM134973 | Oklahoma Center for Microbial Pathogenesis and Immunity | 001 | 6 | NIH | 8/18/2025 | $2,153,497 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 004 | 3 | NIH | 7/16/2025 | $43,459 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 003 | 3 | NIH | 5/2/2025 | $269,870 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 000 | 3 | NIH | 4/18/2025 | $488,913 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI185203 | Targeting chondroitin sulfate proteoglycan 4 (CSPG4) expression as a Clostridioides difficile therapeutic | 000 | 2 | NIH | 4/14/2025 | $357,500 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK131064 | Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | 000 | 4 | NIH | 12/13/2024 | $370,911 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK131064 | Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | 001 | 4 | NIH | 6/18/2025 | $41,212 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY034133 | Correction of diabetic retinopathy by mitochondrial transfer | 001 | 3 | NIH | 4/2/2025 | $554,407 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | D4054837 | Graduate Psychology Education Programs | 00 | 1 | HRSA | 6/12/2025 | $202,794 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DA064398 | Effects of Neurotensin on VTA Neuron Physiology and Methamphetamine Use | 000 | 1 | NIH | 7/7/2025 | $38,696 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DA064398 | Effects of Neurotensin on VTA Neuron Physiology and Methamphetamine Use | 001 | 1 | NIH | 7/7/2025 | $0 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA281098 | Development of contrast agents to facilitate image-guided surgery | 001 | 3 | NIH | 9/15/2025 | $1,728,268 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R33CA253600 | Mobile Health Technology for Personalized Tobacco Cessation Support in Laos | 001 | 5 | NIH | 9/19/2025 | $85,126 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R33CA253600 | Mobile Health Technology for Personalized Tobacco Cessation Support in Laos | 000 | 5 | NIH | 9/18/2025 | $147,907 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK138339 | Role of FBW7 in cystic diseases of the kidney | 000 | 2 | NIH | 6/19/2025 | $480,943 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R33CA253600 | Mobile Health Technology for Personalized Tobacco Cessation Support in Laos | 000 | 5 | NIH | 9/18/2025 | $5,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD109784 | Prevention of Necrotizing Enterocolitis | 001 | 3 | NIH | 4/14/2025 | $40,935 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD109784 | Prevention of Necrotizing Enterocolitis | 000 | 3 | NIH | 1/24/2025 | $368,415 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U54HD113173 | Center for Indigenous Resilience, Culture, and Maternal Health Equity | 000 | 3 | NIH | 8/27/2025 | $1,432,650 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL169530 | Mechanism of F-18-fluorodeoxyglucarate accrual in myocardial injury | 000 | 2 | NIH | 4/3/2025 | $362,500 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U01DK135007 | Identifying Metabolic and Psychosocial Antecedents and Characteristics of youth-onset Type 2 diabetes (IMPACT DM) | 001 | 3 | NIH | 9/9/2025 | $53,098 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U01DK135007 | Identifying Metabolic and Psychosocial Antecedents and Characteristics of youth-onset Type 2 diabetes (IMPACT DM) | 000 | 3 | NIH | 2/14/2025 | $569,717 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | D8854923 | Postdoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene | 04 | 1 | HRSA | 9/25/2025 | $12,931 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | D8854923 | Postdoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene | 03 | 1 | HRSA | 9/19/2025 | -$12,931 |
|
